Drug intelligence / Profile preview

nalmefene cream

Development stage: Discontinued
Lead developer: Serentis
Modality: Small Molecules
Administration: Topical

Overview

SRD174 Cream is a topical formulation of nalmefene, a long-acting opioid antagonist that was investigated for the management of pruritus (itching) associated with atopic dermatitis. The cream was developed to target peripheral opioid receptors with the hypothesis that blocking these receptors would reduce itching sensations in patients with atopic dermatitis. However, clinical trials did not demonstrate efficacy in treating pruritus associated with this condition.

Other names: topical nalmefenenalmefene cream

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on nalmefene cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nalmefene cream.

Explore the full profile